Twist Bioscience (TWST) Cut to Sell at Zacks Investment Research

Zacks Investment Research downgraded shares of Twist Bioscience (NASDAQ:TWST) from a hold rating to a sell rating in a research note issued to investors on Tuesday morning.

According to Zacks, “Twist Bioscience Corporation operates as a biotechnology company. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development and DNA as a digital data storage medium. Twist Bioscience Corporation is headquartered in San Francisco, California. “

Several other analysts have also recently issued reports on TWST. Cowen initiated coverage on shares of Twist Bioscience in a research report on Monday, November 26th. They set an outperform rating on the stock. JPMorgan Chase & Co. initiated coverage on shares of Twist Bioscience in a research report on Monday, November 26th. They set a neutral rating and a $27.00 target price on the stock. Finally, Robert W. Baird initiated coverage on shares of Twist Bioscience in a research report on Monday, November 26th. They set an outperform rating on the stock.

Shares of NASDAQ TWST opened at $21.44 on Tuesday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 7.43 and a current ratio of 7.72. The stock has a market cap of $590.10 million and a PE ratio of -0.84. Twist Bioscience has a 12-month low of $12.38 and a 12-month high of $34.46.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Thursday, February 7th. The company reported ($1.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.33). The firm had revenue of $11.49 million for the quarter, compared to analysts’ expectations of $9.70 million. As a group, sell-side analysts expect that Twist Bioscience will post -4.18 EPS for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Citigroup Inc. purchased a new stake in shares of Twist Bioscience during the 4th quarter valued at about $31,000. American International Group Inc. purchased a new stake in Twist Bioscience in the 4th quarter worth about $77,000. Brandywine Managers LLC purchased a new stake in Twist Bioscience in the 4th quarter worth about $462,000. Dean Capital Investments Management LLC purchased a new stake in Twist Bioscience in the 4th quarter worth about $990,000. Finally, D. E. Shaw & Co. Inc. purchased a new stake in Twist Bioscience in the 4th quarter worth about $1,039,000. Hedge funds and other institutional investors own 22.56% of the company’s stock.

About Twist Bioscience

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.

Recommended Story: Outstanding Shares

Get a free copy of the Zacks research report on Twist Bioscience (TWST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.